Comparison of clinical characteristics between COVID-19 and H7N9 fatal cases : An observational study
Copyright © 2022 Jiang, Liu, Chan, Yin, Huang, Shen, Tu, Kang, Liu, Zhao, Zhang, Xu, Li, Liu and Huang..
Objective: The outbreak of COVID-19 in 2020 is reminiscent of the H7N9 outbreak in 2013, which poses a huge threat to human health. We aim to compare clinical features and survival factors in fatal cases of COVID-19 and H7N9.
Methods: Data on confirmed COVID-19 and H7N9 fatal cases identified in mainland China were analyzed to compare demographic characteristics and clinical severity. Survival curves were estimated by the Kaplan-Meier method and compared using log-rank tests and a restricted mean survival time model. A Cox regression model was used to identify survival factors in fatal cases of COVID-19 and H7N9.
Results: Similar demographic characteristics were observed in fatal cases of COVID-19 and H7N9. The proportion of fatal cases of H7N9 receiving antibiotics, antiviral drugs, and oxygen treatment was higher than that of COVID-19. The potential protective factors for fatal COVID-19 cases were receiving antibiotics (HR: 0.37, 95% CI: 0.22-0.61), oxygen treatment (HR: 0.66, 95% CI: 0.44-0.99), and corticosteroids (HR: 0.46, 95% CI: 0.35-0.62). In contrast, antiviral drugs (HR: 0.21, 95% CI: 0.08-0.56) and corticosteroids (HR: 0.45, 95% CI: 0.29-0.69) were the protective factors for H7N9 fatal cases.
Conclusion: The proportion of males, those having one or more underlying medical condition, and older age was high in COVID-19 and H7N9 fatal cases. Offering antibiotics, oxygen treatment, and corticosteroids to COVID-19 cases extended the survival time. Continued global surveillance remains an essential component of pandemic preparedness.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Frontiers in public health - 10(2022) vom: 02., Seite 1047362 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jiang, Hui [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 16.12.2022 Date Revised 30.01.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fpubh.2022.1047362 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350171467 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350171467 | ||
| 003 | DE-627 | ||
| 005 | 20231226044405.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fpubh.2022.1047362 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1167.xml |
| 035 | |a (DE-627)NLM350171467 | ||
| 035 | |a (NLM)36504959 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jiang, Hui |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of clinical characteristics between COVID-19 and H7N9 fatal cases |b An observational study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2022 | ||
| 500 | |a Date Revised 30.01.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Jiang, Liu, Chan, Yin, Huang, Shen, Tu, Kang, Liu, Zhao, Zhang, Xu, Li, Liu and Huang. | ||
| 520 | |a Objective: The outbreak of COVID-19 in 2020 is reminiscent of the H7N9 outbreak in 2013, which poses a huge threat to human health. We aim to compare clinical features and survival factors in fatal cases of COVID-19 and H7N9 | ||
| 520 | |a Methods: Data on confirmed COVID-19 and H7N9 fatal cases identified in mainland China were analyzed to compare demographic characteristics and clinical severity. Survival curves were estimated by the Kaplan-Meier method and compared using log-rank tests and a restricted mean survival time model. A Cox regression model was used to identify survival factors in fatal cases of COVID-19 and H7N9 | ||
| 520 | |a Results: Similar demographic characteristics were observed in fatal cases of COVID-19 and H7N9. The proportion of fatal cases of H7N9 receiving antibiotics, antiviral drugs, and oxygen treatment was higher than that of COVID-19. The potential protective factors for fatal COVID-19 cases were receiving antibiotics (HR: 0.37, 95% CI: 0.22-0.61), oxygen treatment (HR: 0.66, 95% CI: 0.44-0.99), and corticosteroids (HR: 0.46, 95% CI: 0.35-0.62). In contrast, antiviral drugs (HR: 0.21, 95% CI: 0.08-0.56) and corticosteroids (HR: 0.45, 95% CI: 0.29-0.69) were the protective factors for H7N9 fatal cases | ||
| 520 | |a Conclusion: The proportion of males, those having one or more underlying medical condition, and older age was high in COVID-19 and H7N9 fatal cases. Offering antibiotics, oxygen treatment, and corticosteroids to COVID-19 cases extended the survival time. Continued global surveillance remains an essential component of pandemic preparedness | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a H7N9 | |
| 650 | 4 | |a clinical course | |
| 650 | 4 | |a fatal cases | |
| 650 | 4 | |a protective factors | |
| 650 | 4 | |a survival time | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Oxygen |2 NLM | |
| 650 | 7 | |a S88TT14065 |2 NLM | |
| 700 | 1 | |a Liu, Fangchao |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Ta-Chien |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Jinfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Ruowen |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Tu, Shengjin |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Na |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Di |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Wangli |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Weimin |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Shelan |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Chaolin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in public health |d 2013 |g 10(2022) vom: 02., Seite 1047362 |w (DE-627)NLM23377548X |x 2296-2565 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g day:02 |g pages:1047362 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fpubh.2022.1047362 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |b 02 |h 1047362 | ||